MAY 29, 2014 12:00 PM PDT
Pharmacogenomics and Pharmacometabolomics for Personalized Medicine
Presented at the Clinical Diagnostics and Research Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
36 60 1943

Speakers:
  • President, AACC 2014, Professor of Pathology, Director, Clinical Chemistry, Co-Director, Clinical and Translational Mass Spectrometry Center, Wake Forest University School of Medicine
    Biography
      Steven H. Wong, Ph.D., DABCC (TC), FACB, is Professor of Pathology with tenure, Director of Clinical Chemistry and Toxicology/Core Laboratory, Department of Pathology, Wake Forest School of Medicine. He is Co-Director of Clinical and Translational Mass Spectrometry Center. Dr. Wongs current scientific and clinical interests encompass clinical and translational applications of omics biomarkers for enabling personalized medicine and personalized justice: pharmacogenomics, proteomics, metabolomics, and mass spectrometry for clinical chemistry., TDM with emphasis on immunosuppressant and pain management therapy with adjunct pharmacogenomics and metabolomics., and oral fluid proteome and metabolome for clinical and forensic toxicology/workplace testing. In addition to over 121 publications and 146 abstracts, he edited/co-edited four books including Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. Prior to joining Wake Forest, Dr. Wong was a Professor of Pathology, Director/Co-Director, Clinical Chemistry/Toxicology, TDM, Pharmacogenomics and Proteomics, Department of Pathology, Medical College of Wisconsin. He also served at the Milwaukee County Medical Examiners Office, the University of Connecticut School of Medicine., and Johns Hopkins University School of Medicine. An active AACC member since 1980, Dr. Wong is the current AACC President. He is a member of NACB, and chair of four divisions. Outside AACC, Dr. Wong is a member of the Drug Testing Advisory Board of Substance Abuse and Mental Health Services Administration/DHHS, and a member of the Antibody Committee of the National Cancer Institute/NIH. He is an editorial board member for Pharmacogenomics, Therapeutic Drug Monitoring, Annuals of Clinical & Laboratory Science, the Egyptian Journal of Hospital Medicine, and the Journal of Pediatric Biochemistry, and a past board member for Clinical Chemistry and Laboratory Medicine and Journal of Analytical Toxicology. 

    Abstract:
    Pharmcogenomics (PGx) is the 2nd potential clinical application of genomic medicine, preceded by genomic application for cancer. In the recently published, 2012 Institute of Medicine report on Evolution of Translational Omics: Lessons Learned and the Path Forward , 4 molecular disciplines included genomics, transcriptomics, proteomics and metabolomics. The proper application of genomics/PGx and other omics biomarkers requires development and evaluations, with clinical utilities performed in a CLIA certified laboratory. Further, there is emerging evidence of the bidirectional relationship, possibly modifying the central dogma of molecular biology. A subset of metabolomics - pharmacometabolomics complements PGx by assessing its effect on drug metabolism. Coupled with recent advances in molecular diagnostics such as Next Generation Sequencing, Genome Wide Association Studies, and high resolution LCMSMS, translational PGx and pharmacometabolomics are being rapidly explored to optimize drug therapies by offering the possible practice of Personalized Medicine in transplant, cancer, pain management, and other areas.

    Show Resources
    Loading Comments...